This study compares the impact of the 3 different out-of-pocket maximums proposed in Congress and by the Medicare Payment Advisory Commission.
Sonal Parasrampuria, PhD, MPH
Advertisement
Articles by Sonal Parasrampuria, PhD, MPH
Out-of-pocket (OOP) spending for specialty drugs is substantially higher in Medicare Part D compared with employer-sponsored insurance because of the Part D benefit design.
Advertisement
Latest Updated Articles
- Effects of an Out-of-Pocket Maximum in Medicare Part D
February 7th 2022
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5